Biologic Therapies Summit

Given the limited awareness of non-radiographic axial spondyloarthritis, differentiating this disease from radiographic disease and prescribing appropriate therapy remains a key challenge, according to a presentation at the Biologic Therapies Summit.

While COVID-19 launched cytokine storm syndrome to the forefront of medical research, there is still much to be learned about these hyperactive immune events, according to a presenter at the Biologic Therapies Summit.

Early intervention is critical for patients who are likely to progress to serious complications from systemic sclerosis-associated interstitial lung disease, according to a presenter at the Biologic Therapies Summit.

Although a range of biologic options are available to clinicians treating psoriatic arthritis, it crucial to know which disease domains are involved as this will “dictate treatment,” according to a presenter at the Biologic Therapies Summit.

While certain rheumatology drugs are associated with increased hospitalizations in COVID-19, individuals with rheumatologic diseases largely experience outcomes comparable to general population, according to a presenter at the Biologic Therapies Summit.

VEXAS syndrome is a recently discovered disease that features fever, orchitis, skin nodules and small- or medium-vessel vasculitis, among other symptoms, according to a presenter at the Biologic Therapies Summit.

Treatment with a fixed interval of either 500 mg or 1,000 mg rituximab for at least 2 years is a “reasonable option” for patients with anti-neutrophil cytoplasmic autoantibody vasculitis upon achieving remission, according to a presenter here.

Tocilizumab, the one biologic therapy that has FDA approval for giant cell arteritis, has shown ongoing efficacy in keeping patients in remission and off steroids, according to a pair of presenters at the Biologic Therapies Summit.